Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J. van den Bent, Brigitta G. Baumert, Alba A. Brandes et al.|The Lancet Oncology|2021Cited by 333
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutationsC. Mircea S. Tesileanu, Pim J. French, Wies Vallentgoed et al.|Acta Neuropathologica|2021Cited by 60